Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.50 |
| ▸ | PDE6C | P51160 | 2/20 | 0.50 |
| ▸ | PDE1A | P54750 | 3/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.44 |
| ▸ | PDE9A | O76083 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5085823 | 0.95 | PDE5A (0.56) | PDE5APDE6CPDE1APDE1BPDE1C | |
| SCHEMBL17333641 | 0.88 | PDE5A (0.47) | PDE5APDE6CPDE1APDE1BPDE1C | |
| SCHEMBL6058528 | 0.86 | PDE5A (0.67) | PDE5APDE6CPDE1APDE1BPDE1C | |
| SCHEMBL1872915 | 0.80 | PDE5A (0.58) | PDE5APDE6CPDE1APDE1BPDE1C | |
| SCHEMBL7019558 | 0.77 | PARP1 (0.41) | PDE5APDE6CPDE1APDE1BPDE1C | |
| SCHEMBL5085819 | 0.74 | PDE5A (0.65) | PDE5APDE6CALDH1A1MAPTHTT | |
| SCHEMBL7167750 | 0.72 | PDE5A (0.54) | PDE5APDE6CALDH1A1MAPTHTT | |
| SCHEMBL29611957 | 0.72 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL146830 | 0.72 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL6058531 | 0.71 | PDE5A (0.55) | PDE5APDE6CALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-20060040935-A1 | Method of treating impotence due to spinal cord injury | PFIZER INC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040935-A1 | Method of treating impotence due to spinal cord injury | PDE3A, PDE3B, PDE5A | PDE5A 3/4885PDE6C 16/4885PDE1A 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.